← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Third-generation cephalosporins
ceftriaxone, combinations
J01DD54
Forms & Strengths
- Powder for injection: 250mg, 500mg, 1g, 2g
- Solution for injection: 1g/3.5mL, 2g/7.8mL
- Combination injections with sulbactam: 1g/1g, 2g/1g
Adult Dosing
- Community-acquired pneumonia: 1-2g IV every 12-24 hours
- Hospital-acquired pneumonia: 1-2g IV every 12 hours
- Urinary tract infections: 0.5-1g IV every 12-24 hours
- Skin and soft tissue infections: 1g IV every 12-24 hours
Pediatric Dosing
- For children >12 years: follow adult dosing
- For children <12 years: 50-100mg/kg/day IV divided every 12 hours
- Neonates (0-4 weeks): 50-75mg/kg IV every 12 hours
- Infants and children >4 weeks: 50-100mg/kg/day IV divided every 12 hours
Indications
- Community-acquired pneumonia
- Hospital-acquired pneumonia
- Urinary tract infections
- Skin and soft tissue infections
- Surgical prophylaxis
- Gonorrhea
- Meningitis
Mechanism of Action
- Inhibits cell wall synthesis by binding to penicillin-binding proteins
- Interferes with bacterial cell division and growth
Contraindications
- Known hypersensitivity to ceftriaxone or other cephalosporins
- Hyperbilirubinemic neonates (may displace bilirubin from albumin)
- Concomitant use with calcium-containing IV solutions (precipitation may occur)
Adverse Reactions
- Local injection site reactions
- Gastrointestinal disturbances (diarrhea, nausea, vomiting)
- Allergic reactions (rash, pruritus, anaphylaxis)
- Hypersensitivity reactions
- Central nervous system effects (seizures, encephalopathy)
Drug Interactions
- Aminoglycosides: increased risk of nephrotoxicity
- Calcium-containing IV solutions: precipitation may occur
- Chloramphenicol: antagonistic effects
- Warfarin: increased INR, bleeding risk
Curated Content: Needs Vetting Before Put to Clinical Use